Chimerix

News Releases

2010

Chimerix Broad-Spectrum Antiviral CMX001 Shown in Animal Model to be a Potent Inhibitor of Herpes Simplex Viruses

   

- Preclinical Data Demonstrating CMX001 Penetration of Blood-Brain Barrier and Superiority to Acyclovir Against HSV Infection Published in

- The Journal of Infectious Diseases

RESEARCH TRIANGLE PARK, NC, NOVEMBER 22, 2010 - Chimerix, Inc., a pharmaceutical… > Read More

Chimerix to Present at Piper Jaffray 22nd Annual Health Care Conference

   

Research Triangle Park, NC, November 19, 2010 – Chimerix, Inc., a biopharmaceutical company advancing orally-available antiviral therapeutics to address life-threatening diseases, announced today that Kenneth I. Moch, President and Chief Executive Officer, will present at the… > Read More

Chimerix Presents Update on CMX001 Development to the WHO Advisory Committee on Variola Virus Research

   

- CMX001 Exhibits Broad-Spectrum Potential Against dsDNA Viruses, including Smallpox

GENEVA, SWITZERLAND, AND RESEARCH TRIANGLE PARK, NC, NOVEMBER 17, 2010 - Chimerix, Inc., a pharmaceutical company developing orally-available antiviral therapeutics, today presented… > Read More

Chimerix's PIM Conjugate Technology Reduces Risk of Nephrotoxicity for CMX001 and CMX157

   

- Preclinical Data Presented At Pharmaceutical Sciences World Congress 2010

NEW ORLEANS, LA and RESEARCH TRIANGLE PARK, NC, November 16, 2010 – Scientists from Chimerix, Inc. today presented in vitro data demonstrating that the company’s lipid-conjugated… > Read More

Chimerix Antiviral CMX001 Inhibits JC Virus Replication in Preclinical Study

   

-Additional Evidence of CMX001’s Broad-Spectrum Activity Against Double-Stranded DNA Viruses

-CMX001 and CMX157 Highlighted in Closing Plenary Session

AMSTERDAM, THE NETHERLANDS AND RESEARCH TRIANGLE PARK, NC, NOVEMBER 9, 2010 - Chimerix, Inc.,… > Read More

Chimerix Reaffirms its Commitment to CMX001 as a Medical Countermeasure and Broad-Spectrum Antiviral Agent

   

- Small Business Administration Rules that SIGA Technologies is Not a Small Business, Rendering It Ineligible for BARDA Contract

RESEARCH TRIANGLE PARK, NC, November 7, 2010 - Chimerix, Inc., a pharmaceutical company developing orally-available antiviral therapeutics,… > Read More

CMX001 Shows Potential for Strong Antiviral Activity in Critically Ill Patients with ADV

   

- Outcome Data for Patients Treated with CMX001 Under Emergency-IND Protocol

Presented at the IDSA Annual Meeting

VANCOUVER, CANADA and RESEARCH TRIANGLE PARK, NC, October 21, 2010 - Chimerix, Inc., a pharmaceutical company developing orally-available antiviral… > Read More

Chimerix Antiviral CMX001 Demonstrates Positive Safety and Pharmacokinetics in 46 Patients with Compromised Renal Function

   

- CMX001 Achieves Systemic Exposure and Shows No Evidence of Nephrotoxicity in 46 Patients Treated Under Investigator-held Emergency INDs

Boston, MA and Research Triangle Park, NC, September 15, 2010 - Chimerix, Inc., a pharmaceutical company developing orally-available… > Read More

Chimerix to Present at 9th Annual Bio Investor Forum

   

RESEARCH TRIANGLE PARK, NC, September 28, 2010 - Chimerix, Inc., a pharmaceutical company developing orally-available antiviral therapeutics, announced today that Kenneth I. Moch, President and Chief Executive Officer, will present a corporate overview at the upcoming BIO Investor… > Read More

CMX157 shows potential to treat multi-drug-resistant HIV and improve the activity and toxicity profile of Tenofovir

   

RESEARCH TRIANGLE PARK, NC, July 28, 2010 – Chimerix, Inc., a biopharmaceutical company developing orally-available antiviral therapeutics, today announced the publication of research results demonstrating the potential of CMX157 (hexadecyloxypropyl tenofovir) to effectively… > Read More

 < 1 2 3 4 5 >  Last ›